RenovoRx Inc
RNXT
Company Profile
Business description
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Contact
2570 West El Camino Real
Suite 320
Mountain ViewCA94040
USAT: +1 650 284-4433
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
17
Stocks News & Analysis
stocks
An undervalued stock to buy that even Warren Buffett likes
Trading at an 18% discount, this wide-moat stock is a rare find.
stocks
Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up
The data and AI company is one of the world’s strongest private companies, but a PitchBook report says it’s unattractive at the current price.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,951.00 | 31.90 | 0.36% |
| CAC 40 | 8,154.91 | 15.97 | 0.20% |
| DAX 40 | 25,578.85 | 3.84 | 0.02% |
| Dow JONES (US) | 51,863.69 | 185.14 | -0.36% |
| FTSE 100 | 10,708.33 | 30.68 | -0.29% |
| HKSE | 25,087.75 | 45.04 | 0.18% |
| NASDAQ | 27,244.28 | 122.18 | 0.45% |
| Nikkei 225 | 65,018.95 | 882.70 | 1.38% |
| NZX 50 Index | 13,900.85 | 25.37 | 0.18% |
| S&P 500 | 7,764.64 | 0.06 | -0.00% |
| S&P/ASX 200 | 8,757.80 | 25.90 | 0.30% |
| SSE Composite Index | 3,952.13 | 2.22 | 0.06% |